Back to today’s briefing

Story perspectives

EMA Advocates Biosimilar Reforms for Faster Market Access

4/22/2025

50 7

Summary

Story summary

The European Medicines Agency (EMA) is pushing for vital updates to the Biologics Price Competition and Innovation Act (BPCIA) to simplify the path for biosimilar development in the U.S. These changes promise to cut down on redundant clinical testing, improve patient safety, and speed up market access, but they urgently need regulatory and legislative backing to become a reality.

1 of 1

Story summary

The European Medicines Agency (EMA) is pushing for vital updates to the Biologics Price Competition and Innovation Act (BPCIA) to simplify the path for biosimilar development in the U.S. These changes promise to cut down on redundant clinical testing, improve patient safety, and speed up market access, but they urgently need regulatory and legislative backing to become a reality.